MAP1LC3A

Across TCGA pan-cancer cohorts, MAP1LC3A mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated MAP1LC3A data layer compared with 26 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher MAP1LC3A mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated MAP1LC3A expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

PDAC, GBM, and LSCC are the cancer types where MAP1LC3A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	All	0.870	0.673	.001	31	view →
GBM	OS	Quartile	All	0.244	0.842	.001	11	view →
LSCC	OS	Quartile	All	0.833	0.958	.011	9	view →
UCEC	DFS	Median	III,IV	0.445	0.904	.037	4	view →
LUAD	DFS	Median	II,III,IV	0.766	0.923	.018	3	view →
CCRCC	OS	Median	All	0.817	0.961	.031	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

MAP1LC3A–PDAC (DFS)

Open the PDAC breakdown →